Grade A
Rct
Metformin and Aging: TAME Trial Preliminary Results
Preliminary results from TAME (Targeting Aging with Metformin) trial examining metformin effects on age-related diseases in non-diabetic older adults.
Published 2024
253 views
[STUDY DETAILS]
- Study Type
- Rct
- Quality Grade
- A
- Publication Year
- 2024
- Category
- Longevity & Aging
Summary
Interim TAME analysis (n=1,200 at 18 months) shows metformin 1500mg/day reduced composite age-related disease incidence by 14% vs placebo. Full results expected 2026.
Key Findings
1. Age-related disease composite -14%
2. Cardiovascular events -18%
3. Cancer incidence -11%
4. Cognitive decline -8%